Novartis AG (NVS, $100.59) was a top gainer this month, soaring +20.34%
Novartis AG (NVS, $100.59) has emerged as one of the top gainers in the pharmaceutical industry this month, with an impressive 20.34% increase in its share price. This remarkable growth is a result of several factors, including a generally positive trend in the industry and strong earning results. In this article, we will delve deeper into these contributing factors and discuss the implications of NVS's RSI indicator in the overbought zone.
An analysis of the pharmaceutical industry reveals a generally positive trend, with 88.24% of the 57 major pharmaceutical stocks experiencing an uptrend for the month ending April 24, 2023. This strong performance has undoubtedly had a positive impact on NVS's share price, as the company benefits from the overall bullish sentiment in the sector.
Novartis AG's impressive share price increase can also be attributed to its strong earning results. The company has recently reported positive developments in its drug pipeline, leading to increased investor confidence and a subsequent boost in its stock price. These promising developments, coupled with the company's solid financial performance, have likely played a significant role in the stock's rapid appreciation this month.
The Relative Strength Index (RSI) is a widely-used technical analysis tool that measures the velocity and magnitude of price changes to determine whether a security is overbought or oversold. An RSI value above 70 indicates that a security is overbought, while a value below 30 indicates that it is oversold.
NVS's RSI indicator has been sitting in the overbought zone for 21 days, which could suggest that a price pull-back is imminent. This is because the longer a stock remains in the overbought zone, the more likely it is that investors will start selling to lock in profits, leading to a decrease in demand and a subsequent decline in the stock price.
Novartis AG's remarkable 20.34% increase in share price this month can be attributed to the positive trends in the pharmaceutical industry and the company's strong earning results. However, with its RSI indicator remaining in the overbought zone for an extended period, investors should be cautious and monitor the stock closely for any signs of a potential price pull-back.
NVS in upward trend: 10-day moving average crossed above 50-day moving average on June 16, 2026
The 10-day moving average for NVS crossed bullishly above the 50-day moving average on June 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
NVS moved above its 50-day moving average on June 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NVS advanced for three days, in of 344 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 319 cases where NVS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NVS as a result. In of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for NVS turned negative on July 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.634) is normal, around the industry mean (19.755). P/E Ratio (22.070) is within average values for comparable stocks, (27.844). Projected Growth (PEG Ratio) (4.154) is also within normal values, averaging (3.914). Dividend Yield (0.031) settles around the average of (0.031) among similar stocks. P/S Ratio (5.280) is also within normal values, averaging (4.181).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of health care and nutritional products
Industry PharmaceuticalsMajor
Advertisement